Trials / Not Yet Recruiting
Not Yet RecruitingNCT07166263
Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
Exploratory Study of NK510 Cell Therapy in the Treatment of Recurrent and Refractory Advanced Gastric Cancer and Colorectal Cancer
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer and colorectal cancer.NK510 will be administered by intravenous infusion for systemic therapy and intraperitoneal perfusion therapy. The safety and efficacy of this treatment will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NK510 | NK510 will be administered through intravenous infusion, once a week for a total of six times. |
| DRUG | NK510 | NK510 will be administered through intraperitoneal perfusion on D1, D4, and D7 of the first week for a total of 3 times, with each 3-week cycle constituting a total of 2 cycles. |
Timeline
- Start date
- 2025-11-01
- Primary completion
- 2027-06-01
- Completion
- 2027-12-01
- First posted
- 2025-09-10
- Last updated
- 2025-09-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07166263. Inclusion in this directory is not an endorsement.